Quick Comparison
| Ecnoglutide | Tirzepatide | |
|---|---|---|
| Half-Life | Approximately 7-10 days, supporting once-weekly dosing | 120 hours (5 days) |
| Typical Dosage | Phase 3 trials: 1.2-2.4 mg subcutaneous once weekly with stepwise dose escalation over 8-12 weeks, similar to semaglutide. Optimal maintenance dosing being established for both obesity and type 2 diabetes indications. | Weight management (Zepbound): 2.5 mg subcutaneous once weekly for 4 weeks, increasing by 2.5 mg every 4 weeks to maintenance dose of 5-15 mg once weekly. Diabetes (Mounjaro): same escalation schedule, maintenance 5-15 mg subcutaneous once weekly. |
| Administration | Subcutaneous injection (once weekly) | Subcutaneous injection (weekly) |
| Research Papers | 5 papers | 30 papers |
| Categories |
Mechanism of Action
Ecnoglutide
Ecnoglutide is a long-acting GLP-1 receptor agonist engineered for once-weekly subcutaneous dosing using a structural design distinct from albumin-binding (semaglutide) or PEGylation. The molecule incorporates extended-half-life modifications that resist DPP-4 enzymatic degradation while maintaining high-affinity binding and full agonist activity at the GLP-1 receptor.
Receptor activation produces the standard GLP-1 pharmacology: glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon release from alpha cells, slowed gastric emptying via vagal signalling, and central appetite suppression through hypothalamic and brainstem GLP-1 receptors. The clinical profile in Chinese Phase 3 trials closely mirrors semaglutide — approximately 14-15% body weight loss in obesity studies and substantial HbA1c reductions in type 2 diabetes trials — positioning ecnoglutide as a regional alternative to Wegovy and Ozempic with potentially lower pricing.
Ecnoglutide reflects a broader trend of Chinese biotech companies developing GLP-1 receptor agonists for both domestic and international markets. Sciwind Biosciences has filed for regulatory approval in China and is pursuing international development pathways. The molecule is one of several Chinese-developed GLP-1s approaching commercial launch alongside mazdutide, retatrutide-class triple agonists in early Chinese development, and a wave of biosimilar semaglutide products expected as patents expire in major markets through the late 2020s.
Tirzepatide
Tirzepatide is the first approved dual incretin receptor agonist, simultaneously activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual mechanism represents a paradigm shift in obesity and diabetes treatment because the two receptor systems produce complementary and additive metabolic effects that neither achieves alone.
The GLP-1 receptor component works similarly to semaglutide — suppressing appetite through hypothalamic signaling, slowing gastric emptying, and stimulating glucose-dependent insulin secretion. However, the addition of GIP receptor agonism provides unique benefits. GIP receptors in adipose tissue enhance lipid metabolism and may improve fat storage efficiency, while GIP signaling in the brain appears to amplify the appetite-suppressing effects of GLP-1 through distinct neuronal circuits in the hypothalamus.
At the pancreatic level, the dual stimulation of both GIP and GLP-1 receptors on beta cells produces a more robust insulin secretory response than either pathway alone. Tirzepatide also improves insulin sensitivity in peripheral tissues, reduces hepatic fat content, and lowers triglyceride levels. The molecule is built on a modified GIP peptide backbone with GLP-1 receptor cross-reactivity, attached to a C20 fatty di-acid moiety that enables albumin binding and weekly dosing. Clinical trials have shown weight loss of up to 22.5% of body weight, surpassing GLP-1-only agents.
Risks & Safety
Ecnoglutide
Common
nausea, vomiting, diarrhea, decreased appetite (similar profile to semaglutide).
Serious
pancreatitis, gallstones, dehydration.
Rare
thyroid C-cell tumour class warning, severe allergic reactions. Most safety data so far is from Chinese trial populations; broader safety profile being characterised in international trials.
Tirzepatide
Common
nausea (25-35%), diarrhea, constipation, vomiting, reduced appetite, stomach pain, redness at injection site.
Serious
inflammation of the pancreas (pancreatitis), gallstones, very slow stomach emptying (gastroparesis), low blood sugar if combined with other diabetes medications.
Rare
thyroid tumours seen in animal studies, severe allergic reactions, kidney problems.
Full Profiles
Ecnoglutide →
A long-acting weekly GLP-1 weight loss injection from Chinese biotech Sciwind Biosciences. Uses a special protein-extension technology to last longer in the body than semaglutide. Late-stage Phase 3 trials in China showed body weight loss of 14-15% in obesity and good blood-sugar control in type 2 diabetes. Approval in China is expected first, with international filings to follow. One of several Chinese-developed GLP-1s reaching the global market.
Tirzepatide →
Sold as Mounjaro and Zepbound, this is one of the most effective weight loss medications available. It works by targeting two appetite hormones at once (GIP and GLP-1), making it more powerful than medications like semaglutide that only target one. People in clinical trials lost up to 22.5% of their body weight. Also FDA-approved for type 2 diabetes, and improves cholesterol and blood fat levels.